Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Long-Term study sheds light on rare bone and hormone disorder

NCT ID NCT00209235

Knowledge-focused Sponsor: Connecticut Children's Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 600 people with Albright hereditary osteodystrophy, a rare genetic condition affecting bones and hormones. Researchers are looking at how growth hormone treatment affects height and weight in those with a related hormone problem, and also studying thinking and behavior. The goal is to learn more about the condition and find better ways to manage it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2003

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 months to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for GH study: * Diagnosis of pseudohypoparathyroidism type 1A with mutation confirmation and already enrolled previously. * For the portion of the study in which growth hormone was/is used for participants who are not growth hormone deficient (ie., growth hormone sufficient), the participant had to be over 3 years of age (ie., after 3rd birthday) AND also had to be pre-pubertal at the time of GH initiation; they must have been previously enrolled. * The growth hormone sufficient participants met the FDA-approved criteria for idiopathic short stature or the SGA indication and were previously enrolled. Therefore, for all participants enrolled in the growth hormone portion of this study as of now, the growth hormone was/is used according to FDA-approved indications, and growth hormone use was/is according to standard of care clinical guidelines. Exclusion: * Absence of above diagnosis and failure to meet above criteria Inclusion Criteria for cognitive/behavioral studies: * Confirmed diagnosis of Pseudohypoparathyroidism type 1A and Pseudopseudohypoparathyroidism with mutation confirmation and already enrolled previously. * Ages 4 - 65 yrs Exclusion: * Absence of above Inclusion Criteria for Natural History Study: * Confirmed diagnosis of Pseudohypoparathyroidism type 1A or Pseudopseudohypoparathyroidism with mutation confirmation and also enrolled previously. * Ages 0.2 yrs - 89 yrs Exclusion: * Absence of above

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Albright hereditary osteodystrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior pituitary dwarfism pseudohypoparathyroidism pseudohypoparathyroidism type 1A pseudopseudohypoparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Albright hereditary osteodystrophy Pseudohypoparathyroidism type 1A Pseudopseudohypoparathyroidism

Contacts and locations

Locations

  • Connecticut Children's Medical Center

    Hartford, Connecticut, 06103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.